Valneva Crecimiento futuro
Future controles de criterios 6/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Valneva de 59.4% y 20.4% por año respectivamente. Se prevé que el BPA crezca en un 61.9% al año. Se espera que la rentabilidad financiera sea de 61.1% en 3 años.
Información clave
59.4%
Tasa de crecimiento de los beneficios
61.86%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 58.7% |
| Tasa de crecimiento de los ingresos | 20.4% |
| Rentabilidad financiera futura | 61.08% |
| Cobertura de analistas | Good |
| Última actualización | 01 Jun 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • Jun 13
VLA: Future Travel Vaccines And Lyme Franchise Will Drive Reassessment
Analysts have reduced their price target on Valneva from €10.00 to €7.50, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E multiples as reflected in the latest fair value analysis. What's in the News Valneva revised its 2026 product sales guidance to a range of €135 million to €150 million, with total revenue guidance set at €145 million to €160 million, citing an emerging adverse trend in travel vaccine uptake across key markets driven by geopolitical factors.
Actualización de narrativa • May 30
VLA: Weaker Travel Vaccine Demand Will Drive Cautious View On Shares
Analysts have slightly reduced their Valneva price target from €2.15 to €2.10, citing revised assumptions around revenue growth, profit margins and a higher implied future P/E multiple in their updated models. What's in the News Valneva adjusted its 2026 guidance, setting product sales in a range of €135 million to €150 million and total revenue guidance at €145 million to €160 million, citing an emerging adverse trend in travel vaccine uptake across key markets linked to geopolitical factors (Corporate Guidance, Lowered).Artículo de análisis • May 15
€5.28: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Valneva SE ( EPA:VLA ) just released its latest first-quarter report and things are not looking great. Statutory...Actualización de narrativa • May 03
VLA: Lyme Vaccine Progress And Equity Raise Will Shape Balanced Outlook
Analysts have reduced their price target for Valneva from €3.25 to €2.15, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples. What's in the News Valneva filed a follow on equity offering of €37.03 million, covering 15,893,817 ordinary shares at €2.33 per share with attached warrants, under Regulation S (Key Developments).Actualización de narrativa • Apr 18
VLA: Lyme Vaccine Progress Will Support Earnings Despite Chikungunya Setback
Analysts have kept their Valneva price target steady at €3.25, citing updated assumptions for discount rate, revenue growth, profit margins and future P/E that broadly support the prior valuation level. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial results for their 6-valent OspA-based Lyme disease vaccine candidate PF-07307405, with efficacy above 70% in reducing confirmed Lyme cases in two pre specified analyses and no safety concerns identified at the time of analysis.Actualización de narrativa • Apr 03
VLA: Lyme Vaccine Progress Will Offset Chikungunya Headwinds Over Time
Analysts have raised their Valneva price target from €2.95 to €3.25, citing updated assumptions around revenue growth, profit margins, and a slightly lower future P/E multiple as the main factors behind the change. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial data for their investigational 6 valent OspA based Lyme disease vaccine candidate, with efficacy readings in prespecified analyses and Pfizer planning regulatory submissions after reviewing the results and safety profile (Product related announcement).
Actualización de narrativa • Mar 20
VLA: Vaccine Partnerships And Guidance Will Drive Bullish Repricing Potential
Analysts have nudged their price target on Valneva slightly lower to about €6.96 from roughly €6.99, reflecting updated assumptions around discount rates, revenue growth, profit margins and future price-to-earnings levels. What's in the News Elaris FlexCo signed an exclusive global license agreement for Valneva's Clostridioides difficile vaccine candidate VLA84, with plans to use the antigen technology in a next generation program and potential milestone and royalty payments tied to future development, regulatory and commercial outcomes (Key Developments).Actualización de narrativa • Mar 06
VLA: Future Travel Vaccine Franchise And Real World Data Will Drive Reassessment
Analysts have reaffirmed their €10.00 price target for Valneva, with updated assumptions showing a slightly higher discount rate and profit margin, alongside a lower future P/E, suggesting a more balanced view of risk and earnings potential. What's in the News Valneva issued earnings guidance for 2026, expecting total revenues of €155 million to €170 million, with product sales of €145 million to €160 million.Actualización de narrativa • Feb 20
VLA: Future Lyme Vaccine Milestones Will Shape Bullish Repricing Potential
Analysts have adjusted their fair value estimate for Valneva from €6.51 to about €6.99. This change reflects updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples.Actualización de narrativa • Feb 05
VLA: Chikungunya Safety Setbacks Will Weigh On Long Term Earnings Potential
Analysts have reduced their price target on Valneva from €3.25 to €2.95, citing updated assumptions for revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Valneva and Instituto Butantan launched a Pilot Vaccination Strategy in Brazil using single shot chikungunya vaccine IXCHIQ, aiming for 20% to 40% coverage of adults aged 18 to 59 in ten municipalities as part of post marketing effectiveness and safety studies (Key Developments).Actualización de narrativa • Jan 22
VLA: Future Vaccine Pipeline Progress Will Support Higher Market Reassessment
Analysts have lifted their fair value estimate for Valneva from €9.50 to €10.00, pointing to adjusted assumptions around discount rates, revenue growth, profit margins and future P/E as the key drivers of the updated price target. What's in the News Valneva decided to voluntarily withdraw the BLA and IND for its chikungunya vaccine IXCHIQ in the US after the FDA suspended the license in August 2025 and later placed the IND on clinical hold following a newly reported foreign serious adverse event that may be plausibly related to vaccination, while causality has not been determined and no active vaccination studies are ongoing (company announcement).Actualización de narrativa • Jan 07
VLA: Chikungunya Commercial Uncertainty Will Undermine Long Term Earnings Potential
Analysts have adjusted their price targets for Valneva, with updated assumptions that include a discount rate of 6.76%, revenue growth of 9.16%, a profit margin of 26.93% and a forward P/E of 13.87x, reflecting a recalibration of expectations around the company’s risk profile and earnings outlook. What's in the News Valneva and Serum Institute of India agreed to discontinue their license deal for the single shot chikungunya vaccine, with Valneva regaining full rights to manage supply and commercialization in endemic high risk countries within the funding framework agreed with CEPI and the European Union (Client Announcements).Actualización de narrativa • Dec 14
VLA: Higher Long Term Profit Hopes Will Not Offset Rising Risk
Analysts have trimmed their price target for Valneva from €3.75 to €3.25, reflecting higher perceived risk despite more optimistic long term assumptions for revenue growth and profitability. What's in the News Positive Phase 2 antibody persistence and safety data in 304 children for single shot chikungunya vaccine IXCHIQ, supporting full dose selection and planned Phase 3 development in pediatrics (company announcement) Phase 2 Lyme disease vaccine candidate VLA15 shows strong booster response and favorable safety across age groups, reinforcing partnership with Pfizer ahead of planned 2026 BLA and MAA filings, subject to positive Phase 3 results (company announcement) Strategic reorganization to concentrate French operations in Lyon and close the Nantes site.Artículo de análisis • Oct 01
Subdued Growth No Barrier To Valneva SE (EPA:VLA) With Shares Advancing 29%
Despite an already strong run, Valneva SE ( EPA:VLA ) shares have been powering on, with a gain of 29% in the last...Artículo de análisis • Sep 10
Is Valneva (EPA:VLA) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Actualización de narrativa • Aug 24
Rapid Lyme Vaccine Development And Rising Preventative Healthcare Will Shape Future Markets
Valneva's substantial improvement in net profit margin and sharp reduction in future P/E have led to a notable upward revision in the consensus analyst price target from €6.97 to €7.48. What's in the News Health Canada granted marketing authorization for IXCHIQ, Valneva’s single-dose chikungunya vaccine, for individuals aged 12 years and older, supported by robust antibody persistence and safety data.Artículo de análisis • Jul 24
Valneva SE's (EPA:VLA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Valneva SE ( EPA:VLA ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month...Nueva narrativa • May 14
Upcoming Lyme Vaccine Data Will Unlock Market Opportunities
Potential success of the Lyme disease vaccine could significantly boost future revenue and earnings through strategic regulatory filings and commercialization milestones.Artículo de análisis • Feb 20
Valneva SE (EPA:VLA) Analysts Just Slashed Next Year's Revenue Estimates By 13%
Market forces rained on the parade of Valneva SE ( EPA:VLA ) shareholders today, when the analysts downgraded their...Artículo de análisis • Feb 06
Valneva SE (EPA:VLA) Stock Catapults 35% Though Its Price And Business Still Lag The Industry
Valneva SE ( EPA:VLA ) shares have had a really impressive month, gaining 35% after a shaky period beforehand. Not all...Artículo de análisis • Nov 22
Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Valneva SE ( EPA:VLA ) share price has dived 25% in the last thirty days...Artículo de análisis • Nov 10
€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Valneva SE ( EPA:VLA ) just released its latest quarterly results and things are looking bullish. Results overall were...Artículo de análisis • Sep 19
Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive
Valneva SE ( EPA:VLA ) shares have had a horrible month, losing 29% after a relatively good period beforehand. For any...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 251 | 39 | 8 | 82 | 8 |
| 12/31/2027 | 294 | 71 | 92 | 110 | 9 |
| 12/31/2026 | 152 | -66 | -62 | -62 | 9 |
| 3/31/2026 | 156 | -138 | -48 | -45 | N/A |
| 12/31/2025 | 175 | -115 | -57 | -53 | N/A |
| 9/30/2025 | 180 | -102 | -19 | -19 | N/A |
| 6/30/2025 | 196 | -67 | -27 | -12 | N/A |
| 3/31/2025 | 186 | -80 | -60 | -47 | N/A |
| 12/31/2024 | 170 | -12 | -84 | -67 | N/A |
| 9/30/2024 | 159 | -7 | -169 | -143 | N/A |
| 6/30/2024 | 156 | -32 | -215 | -204 | N/A |
| 3/31/2024 | 153 | -24 | -222 | -207 | N/A |
| 12/31/2023 | 154 | -101 | -217 | -203 | N/A |
| 9/30/2023 | 223 | -113 | -208 | -193 | N/A |
| 6/30/2023 | 426 | -7 | -231 | -211 | N/A |
| 3/31/2023 | 373 | -135 | -267 | -243 | N/A |
| 12/31/2022 | 361 | -143 | -275 | -245 | N/A |
| 9/30/2022 | 439 | 73 | -195 | -149 | N/A |
| 6/30/2022 | 304 | -159 | -177 | -108 | N/A |
| 3/31/2022 | 347 | -72 | -83 | 2 | N/A |
| 12/31/2021 | 348 | -73 | -16 | 77 | N/A |
| 9/30/2021 | 121 | -248 | 15 | 97 | N/A |
| 6/30/2021 | 110 | -125 | 51 | 109 | N/A |
| 3/31/2021 | 98 | -91 | 147 | 182 | N/A |
| 12/31/2020 | 110 | -64 | 118 | 138 | N/A |
| 9/30/2020 | 104 | -62 | 67 | 78 | N/A |
| 6/30/2020 | 120 | -25 | 97 | 105 | N/A |
| 3/31/2020 | 127 | -8 | -7 | 3 | N/A |
| 12/31/2019 | 126 | -2 | N/A | 6 | N/A |
| 9/30/2019 | 116 | 4 | N/A | 10 | N/A |
| 6/30/2019 | 109 | 1 | N/A | 16 | N/A |
| 3/31/2019 | 116 | 7 | N/A | 17 | N/A |
| 12/31/2018 | 113 | 3 | N/A | 16 | N/A |
| 9/30/2018 | 107 | -7 | N/A | 6 | N/A |
| 6/30/2018 | 110 | -7 | N/A | 10 | N/A |
| 3/31/2018 | 108 | -8 | N/A | 5 | N/A |
| 12/31/2017 | 105 | -11 | N/A | 13 | N/A |
| 9/30/2017 | 103 | -11 | N/A | 17 | N/A |
| 6/30/2017 | 100 | -14 | N/A | 19 | N/A |
| 3/31/2017 | 102 | -46 | N/A | 25 | N/A |
| 12/31/2016 | 98 | -49 | N/A | 7 | N/A |
| 9/30/2016 | 93 | -63 | N/A | 4 | N/A |
| 6/30/2016 | 96 | -61 | N/A | -5 | N/A |
| 3/31/2016 | 89 | -35 | N/A | -17 | N/A |
| 12/31/2015 | 83 | -21 | N/A | -20 | N/A |
| 9/30/2015 | 74 | -16 | N/A | -24 | N/A |
| 6/30/2015 | 65 | -13 | N/A | -19 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que VLA sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.5%).
Beneficios vs. Mercado: Se prevé que VLA sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que VLA sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (20.4% al año) de VLA crezcan más rápidamente que los del mercado French (5.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (20.4% al año) de VLA crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de VLA sea muy elevada dentro de 3 años (61.1%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/19 23:55 |
| Precio de las acciones al final del día | 2026/06/19 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Valneva SE está cubierta por 15 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Vladimira Urbankova | Erste Group Bank AG |
| Simon Scholes | First Berlin Equity Research GmbH |
| Rajan Sharma | Goldman Sachs |